These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35763342)

  • 1. A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study.
    Lipsmeier F; Simillion C; Bamdadian A; Tortelli R; Byrne LM; Zhang YP; Wolf D; Smith AV; Czech C; Gossens C; Weydt P; Schobel SA; Rodrigues FB; Wild EJ; Lindemann M
    J Med Internet Res; 2022 Jun; 24(6):e32997. PubMed ID: 35763342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and initial validation of 'HD-Mobile', a smartphone application for remote self-administration of performance-based cognitive measures in Huntington's disease.
    McLaren B; Andrews SC; Glikmann-Johnston Y; Mercieca EC; Murray NWG; Loy C; Bellgrove MA; Stout JC
    J Neurol; 2021 Feb; 268(2):590-601. PubMed ID: 32880724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.
    Cohen S; Waks Z; Elm JJ; Gordon MF; Grachev ID; Navon-Perry L; Fine S; Grossman I; Papapetropoulos S; Savola JM
    BMC Med Inform Decis Mak; 2018 Dec; 18(1):138. PubMed ID: 30572891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease.
    Lipsmeier F; Taylor KI; Postuma RB; Volkova-Volkmar E; Kilchenmann T; Mollenhauer B; Bamdadian A; Popp WL; Cheng WY; Zhang YP; Wolf D; Schjodt-Eriksen J; Boulay A; Svoboda H; Zago W; Pagano G; Lindemann M
    Sci Rep; 2022 Jul; 12(1):12081. PubMed ID: 35840753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease.
    Boileau NR; Stout JC; Paulsen JS; Cella D; McCormack MK; Nance MA; Frank S; Lai JS; Carlozzi NE
    J Huntingtons Dis; 2017; 6(3):201-215. PubMed ID: 28968239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of virtual visits in Huntington disease.
    Bull MT; Darwin K; Venkataraman V; Wagner J; Beck CA; Dorsey ER; Biglan KM
    J Huntingtons Dis; 2014; 3(2):189-95. PubMed ID: 25062861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures.
    Lai JS; Goodnight S; Downing NR; Ready RE; Paulsen JS; Kratz AL; Stout JC; McCormack MK; Cella D; Ross C; Russell J; Carlozzi NE
    Qual Life Res; 2018 Mar; 27(3):811-822. PubMed ID: 29222609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
    Lipsmeier F; Taylor KI; Kilchenmann T; Wolf D; Scotland A; Schjodt-Eriksen J; Cheng WY; Fernandez-Garcia I; Siebourg-Polster J; Jin L; Soto J; Verselis L; Boess F; Koller M; Grundman M; Monsch AU; Postuma RB; Ghosh A; Kremer T; Czech C; Gossens C; Lindemann M
    Mov Disord; 2018 Aug; 33(8):1287-1297. PubMed ID: 29701258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study.
    Pratap A; Grant D; Vegesna A; Tummalacherla M; Cohan S; Deshpande C; Mangravite L; Omberg L
    JMIR Mhealth Uhealth; 2020 Oct; 8(10):e22108. PubMed ID: 33107827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor outcome measures in Huntington disease clinical trials.
    Reilmann R; Schubert R
    Handb Clin Neurol; 2017; 144():209-225. PubMed ID: 28947119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Determinants of Dual Tasking in People With Premanifest Huntington Disease.
    Reyes A; Bartlett DM; Rankin TJ; Zaenker P; Turner K; Teo WP; Fu SC; Domingos J; Georgiou-Karistianis N; Ziman M; Cruickshank TM
    Phys Ther; 2021 Apr; 101(4):. PubMed ID: 33482001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital measures of respiratory and upper limb function in spinal muscular atrophy: design, feasibility, reliability, and preliminary validity of a smartphone sensor-based assessment suite.
    Perumal TM; Wolf D; Berchtold D; Pointeau G; Zhang YP; Cheng WY; Lipsmeier F; Sprengel J; Czech C; Chiriboga CA; Lindemann M;
    Neuromuscul Disord; 2023 Nov; 33(11):845-855. PubMed ID: 37722988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD).
    Carlozzi NE; Boileau NR; Paulsen JS; Downing NR; Ready R; Perlmutter JS; Cella D; Chou KL; McCormack MK; Barton S; Lai JS
    Qual Life Res; 2020 May; 29(5):1393-1403. PubMed ID: 31853881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease.
    Orth M; Schippling S; Schneider SA; Bhatia KP; Talelli P; Tabrizi SJ; Rothwell JC
    J Neurol Neurosurg Psychiatry; 2010 Mar; 81(3):267-70. PubMed ID: 19828482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease.
    McAllister B; Gusella JF; Landwehrmeyer GB; Lee JM; MacDonald ME; Orth M; Rosser AE; Williams NM; Holmans P; Jones L; Massey TH;
    Neurology; 2021 May; 96(19):e2395-e2406. PubMed ID: 33766994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study.
    Beckmann H; Bohlen S; Saft C; Hoffmann R; Gerss J; Muratori L; Ringelstein EB; Landwehrmeyer GB; Reilmann R
    Gait Posture; 2018 May; 62():451-457. PubMed ID: 29660633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.
    Carlozzi NE; Goodnight S; Kratz AL; Stout JC; McCormack MK; Paulsen JS; Boileau NR; Cella D; Ready RE
    J Huntingtons Dis; 2019; 8(4):467-482. PubMed ID: 31424415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?
    Carlozzi NE; Schilling S; Kratz AL; Paulsen JS; Frank S; Stout JC
    Qual Life Res; 2018 Oct; 27(10):2541-2555. PubMed ID: 29909483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
    Tabrizi SJ; Langbehn DR; Leavitt BR; Roos RA; Durr A; Craufurd D; Kennard C; Hicks SL; Fox NC; Scahill RI; Borowsky B; Tobin AJ; Rosas HD; Johnson H; Reilmann R; Landwehrmeyer B; Stout JC;
    Lancet Neurol; 2009 Sep; 8(9):791-801. PubMed ID: 19646924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability and minimal detectable change of physical performance measures in individuals with pre-manifest and manifest Huntington disease.
    Quinn L; Khalil H; Dawes H; Fritz NE; Kegelmeyer D; Kloos AD; Gillard JW; Busse M;
    Phys Ther; 2013 Jul; 93(7):942-56. PubMed ID: 23520147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.